Bausch Health Companies vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bausch Health Companies Inc (BHC)

Q3 202612 Jul – 16 Sep 2026

▲4

BHC's core business is beating expectations and expanding abroad

Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.
This is the single biggest new force behind BHC's move, directly driving the 28% share surge.
Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.
Explains which parts of the business are actually powering the earnings beat, not just the headline number.
PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.
A concrete regulatory win that opens a new paying market for a BHC product.
Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.
Shows a new international growth avenue, but one that is still small relative to the core earnings story.

August 202612 Jul – 16 Sep 2026

▲4

BHC's core business is beating expectations and expanding abroad

Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.
This is the single biggest new force behind BHC's move, directly driving the 28% share surge.
Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.
Explains which parts of the business are actually powering the earnings beat, not just the headline number.
PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.
A concrete regulatory win that opens a new paying market for a BHC product.
Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.
Shows a new international growth avenue, but one that is still small relative to the core earnings story.

Latest12 Jul – 16 Sep 2026

▲4

BHC's core business is beating expectations and expanding abroad

Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.
This is the single biggest new force behind BHC's move, directly driving the 28% share surge.
Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.
Explains which parts of the business are actually powering the earnings beat, not just the headline number.
PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.
A concrete regulatory win that opens a new paying market for a BHC product.
Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.
Shows a new international growth avenue, but one that is still small relative to the core earnings story.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.